Effect of accurate heart delineation on cardiac dose during the CONVERT Trial.
Affiliation
Mount Vernon Cancer Centre, Northwood, UKIssue Date
2017-03-31
Metadata
Show full item recordAbstract
This study investigates the effect of deviation from protocol in heart delineation for the CONVERT Trial ( ClinicalTrials.gov Identifier NCT00433563) quality assurance (QA) programme, and the effect of that on mean cardiac dose and percentage of heart volume receiving ≥5Gy (V5%) and ≥30Gy (V30%).Citation
Effect of accurate heart delineation on cardiac dose during the CONVERT Trial. 2017, Br J RadiolJournal
The British Journal of RadiologyDOI
10.1259/bjr.20170036PubMed ID
28362511Type
ArticleLanguage
enISSN
1748-880Xae974a485f413a2113503eed53cd6c53
10.1259/bjr.20170036
Scopus Count
Collections
Related articles
- Cardiac Dose and Survival After Stereotactic Body Radiotherapy for Early-stage Non-Small-cell Lung Cancer.
- Authors: Tembhekar AR, Wright CL, Daly ME
- Issue date: 2017 May
- Is pre-trial quality assurance necessary? Experiences of the CONVERT Phase III randomized trial for good performance status patients with limited-stage small-cell lung cancer.
- Authors: Groom N, Wilson E, Lyn E, Faivre-Finn C
- Issue date: 2014 May
- Thorough design and pre-trial quality assurance (QA) decrease dosimetric impact of delineation and dose planning variability in the STRICTLUNG and STARLUNG trials for stereotactic body radiotherapy (SBRT) of central and ultra-central lung tumours.
- Authors: Hoffmann L, Persson GF, Nygård L, Nielsen TB, Borrisova S, Gaard-Petersen F, Josipovic M, Khalil AA, Kjeldsen R, Knap MM, Kristiansen C, Møller DS, Ottosson W, Sand H, Thing R, Pøhl M, Schytte T
- Issue date: 2022 Jun
- Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
- Authors: Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, Bezjak A, Cardenal F, Fournel P, Harden S, Le Pechoux C, McMenemin R, Mohammed N, O'Brien M, Pantarotto J, Surmont V, Van Meerbeeck JP, Woll PJ, Lorigan P, Blackhall F, CONVERT Study Team
- Issue date: 2017 Aug
- Cardiac Dose in Locally Advanced Lung Cancer: Results From a Statewide Consortium.
- Authors: Dess RT, Sun Y, Muenz DG, Paximadis PA, Dominello MM, Grills IS, Kestin LL, Movsas B, Masi KJ, Matuszak MM, Radawski JD, Moran JM, Pierce LJ, Hayman JA, Schipper MJ, Jolly S, Michigan Radiation Oncology Quality Consortium
- Issue date: 2020 Jan-Feb